News

By ...

April 20, 2018

Brazilian Superior Court of Justice decides its first mailbox case

On April 17, 2018 the Superior Court of Justice had the opportunity to analyze the first Special Appeal addressing the term of protection for mailbox patents and decided that these patents are not entitled to the minimum term of protection provided by article 40, sole paragraph of Brazilian Industrial Property Act. Mailbox patents are patents for pharmaceuticals and agrochemicals that were filed between the 1st of January, 1995 and 14th of May, 1997– when the TRIPs agreement was already in force in Brazil, but there was no act of law in place authorizing the protection of patents in these fields.
 
The current Brazilian Industrial Property Act established that these patents could be granted following the rules of head of article 40 (which grants a 20-year term of protection counting from the filing date). The case at stake was related to one of the patents for the drug Soliris, whose patent was granted following article 40, sole paragraph of Brazilian Industrial Property Act – which allows a minimum term of protection of 10 years from grant irrespective of the patent’s filing date. Although the term of protection was limited to 20 years from filing, there was no discussion about the patentability requirements. The full content of the decision is available here.
 
Back

Last by ...

September 9, 2024

Kasznar Leonardos wins LMG Life Sciences

We are honored to announce that Kasznar Leonardos has won the Firm of the Year: Brazil award at the LMG Life Sciences! Kasznar Leonardos wins LMG Life Sciences

Ler notícia

July 5, 2021

Personalised medicine in Brazil: IP and regulatory challenges

Our partners Anderson Ribeiro, Aline Ferreira and Priscila Kashiwabara authored the chapter "Personalised medicine in Brazil: IP and regulatory challenges". This article first Personalised medicine in Brazil: IP and regulatory challenges

Ler notícia

June 24, 2021

Text of the Business Environment Bill is approved by the Chamber of Representatives, and it ends the prior approval for pharmaceutical patents, in addition to bringing relevant changes to trade names

Ler notícia
plugins premium WordPress